Auris Medical Holding AG Announces Notice of Allowance from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auris Medical Holding AG Announces Notice of Allowance from USPTO Related to Treating Middle Ear Diseases with Poloxamer-Based Fluoroquinolone Compositions

ZUG, Switzerland, May 18, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (Nasdaq: EARS ), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent (14/317,319) relating to methods of treating inner or middle ear diseases with intratympanic injections of poloxamer-based compositions. The claims are directed to the use of fluoroquinolone antibiotics in poloxamer 407 compositions under certain specifications. The patent is based on a continuation filing related to US patent application 11/992,632, with priority date of September 28, 2005, which discloses the use of various biocompatible polymers for the controlled release of various active substances for the treatment of diseases of the inner or middle ear.     "Auris Medical continues to build and reinforce its intellectual property portfolio," commented Thomas Meyer, Auris Medical's founder, Chairman and CEO. "We are very pleased to have received the Notice of Allowance for the fluoroquinolone-poloxamer patent which goes back to our pioneering work on the use of biocompatible polymers for targeted, local delivery of therapeutic agents to the inner or middle ear."   

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".

Forward-Looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's prospectus relating to its Registration Statement on Form F-1, as amended, and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contact: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, matthew@lifesciadvisors.com

Auris Medical NoA Poloxamer Patent http://hugin.info/160190/R/1922095/688976.pdf

HUG#1922095

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 302

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Energy: Upgrading America's Aging Power Grid

Updated Category News Views 219

The Energy Conundrum Let’s face it, folks, the electric grid we’re using is like a beat-up old car—driving it won’t get any easier unless we pour in some cash and elbow grease. We all know increasing demand for power is putting the squeeze on the infrastructure, and everybody from policymakers to average homeowners is feeling the pinch. Do a little research (or...

Continue Reading
Cove Capital Investments Boosts Annual Distribution Rates Again

Updated Category News Views 69

Cove Capital Investments Announces Distribution Rate Increase The recent announcement regarding the increase in distribution rates by Cove Capital Investments highlights the success of its unique value-add strategy. This strategy is elaborated in the Private Placement Memorandum when the multifamily offering was made available to accredited investors. Performance of Cove...

Continue Reading
Broadcom Surges in After-Hours Trading on Stellar Earnings

Updated Category News Views 268

Broadcom Inc Reports Strong Earnings Broadcom Inc (NASDAQ: AVGO) experienced a remarkable 12.82% increase in its shares during after-hours trading after unveiling its first-quarter results. This rally followed a 6.33% decline during the regular trading hours, which was part of a larger trend of selloffs in the artificial intelligence (AI) chip market. Significant...

Continue Reading
Recent Downgrades: Analysts Weigh In on Key Stocks

Updated Category News Views 162

Analysts' Outlook on Key Stocks Recent changes from top Wall Street analysts revealed a shift in outlook on several prominent companies. Their evaluations often impact market trends and investor sentiment towards various stocks. Invivyd Inc Downgraded D. Boral Capital's Jason Kolbert downgraded the rating for Invivyd Inc (NASDAQ: IVVD) from Buy to Hold. On the trading...

Continue Reading
Innovative Grip Module Redefines Firearm Handling Experience

Updated Category News Views 299

Revolutionizing Firearm Grip with Innovative Design In the realm of firearm accessories, innovation often leads to transformative user experiences. One such breakthrough comes in the form of the 2911 Grip Module. This specially designed grip module addresses the common issues faced by firearm enthusiasts, offering a solution that enhances both comfort and usability. What...

Continue Reading